肝移植后粉碎索磷布韦/维帕他韦与大剂量泮托拉唑联用实现丙肝病毒清除
一例31岁丙肝阴性女性接受丙肝NAT阳性供肝后,因黏膜感染、消化道出血、坏死性胰腺炎等需脂质体两性霉素B和泮托拉唑80mg每日两次,经鼻胃管给予粉碎索磷布韦/维帕他韦,4周内丙肝病毒清除,但12周持续病毒学应答前死亡。
要点
- 粉碎索磷布韦/维帕他韦经鼻胃管给药可用于肝移植后多重吸收顾虑患者。
- 与泮托拉唑80mg每日两次联用下仍观察到4周内丙肝病毒清除。
- 该患者因死亡未能评估12周持续病毒学应答。
核心结论
- 肝移植患者存在多重吸收顾虑时,粉碎索磷布韦/维帕他韦经鼻胃管给药仍可实现丙肝病毒清除。
研究设计与样本
- 病例报告:一例31岁丙肝阴性女性接受丙肝NAT阳性供肝移植。
主要发现
- 治疗后4周内观察到丙肝病毒清除。
- 患者因死亡未评估12周持续病毒学应答。
关键数值与推荐
- 粉碎索磷布韦/维帕他韦与30mL水混合经鼻胃管每日给药。
- 泮托拉唑剂量为80mg每日两次。
临床怎么用
- 肝移植后存在吸收顾虑且需大剂量质子泵抑制剂时,可考虑粉碎索磷布韦/维帕他韦经鼻胃管给药并每周监测病毒载量。
局限性
- 单例病例报告,证据等级有限。
- 患者死亡未获得12周持续病毒学应答数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Direct-acting antivirals (DAAs) allow for successful transplantation of livers from hepatitis C nucleic acid test (NAT)-positive donors to negative recipients. However, limited data exist to support crushing DAAs in patients with multiple absorption concerns or significant drug interactions. SUMMARY: Crushed sofosbuvir/velpatasvir has been successfully used in nontransplant patients with dysphagia, but data in transplant patients with absorption concerns are limited. A 31-year-old hepatitis C-negative female underwent liver transplantation from a hepatitis C NAT-positive donor. Her postoperative course was complicated by a mucormycosis infection, gastrointestinal bleed, and necrotizing pancreatitis requiring treatment with liposomal amphotericin B and pantoprazole 80 mg twice daily. Surgical interventions included an above-the-knee amputation and ileostomy. Hepatitis C treatment was initially delayed because of concern for reduced absorption with crushed DAA administration through the nasogastric (NG) tube, high ileostomy output, gastrointestinal bleed, pancreatitis, and a known drug interaction with pantoprazole. One month after transplantation, the patient's bilirubin level remained elevated and hepatitis C treatment was initiated with sofosbuvir/velpatasvir. Crushed sofosbuvir/velpatasvir was mixed with 30 mL of water and administered through the NG tube daily. Hepatitis C viral loads were obtained weekly during treatment to monitor efficacy. Although the patient died before evaluation of sustained virological response at 12 weeks, hepatitis C viral clearance was observed within 4 weeks of initiating treatment. CONCLUSION: A liver transplant patient exhibited viral clearance of hepatitis C following administration of crushed sofosbuvir/velpatasvir in the setting of multiple absorption concerns.
引用
- Pluckrose DM, Szczepanik A, Bova SE, et al. Hepatitis C viral clearance with coadministration of crushed sofosbuvir/velpatasvir and high-dose pantoprazole after liver transplantation. Am J Health Syst Pharm. 2022. PMID: 35675479. doi:10.1093/ajhp/zxac153
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。